De-Escalated Adjuvant Radiation Therapy in Patients With HPV-Positive Oropharyngeal Cancer

1

The MC1273 phase 2 study evaluated de-escalated adjuvant radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma.
2

De-escalated therapy resulted in high local regional tumor control rates and reduced toxic effects compared to standard treatment.
3

DART was adopted as standard care due to improvements in swallow function, speech, and overall quality of life for patients.
4

A retrospective cohort study analyzed outcomes of patients treated with DART both on study and off study in clinical practice.
5

Data analysis included survival outcomes and patient characteristics, ensuring ethical data use and adherence to reporting guidelines.

Jama Network Open

by Cecelia M. Hidalgo, Aaron W. Bogan, Katelyn S. Rourk, Hannah Q. Baratz, Daniel G. Eyassu, Katharine A. Price, Eric J. Moore, Samir H. Patel, Michael L. Hinni, Michelle A. Neben-Wittich, Yolanda I. Garces, Lisa A. McGee, Scott C. Lester, Jessica Wilson, Jean-Claude M. Rwigema, Ashish V. Chintakuntlawar, Homan Mohammadi, Adam L. Holtzman, Daniel L. Price, Jeffrey R. Janus, Joaquin J. Garcia, Robert L. Foote, Kendall K. Tasche, Daniel J. Ma, Kathryn M. Van Abel, Linda X. Yin, David M. Routman
May 18, 2026

1